[Skip to Navigation]
Sign In
Cancer Care Chronicles
September 2017

Escalation of Commitment in Treatment Decisions Near the End of Life

Author Affiliations
  • 1Unité de Soins Continus, Cliniques Universitaires Saint-Luc, Brussels, Belgium
  • 2IREC, Université Catholique de Louvain, Brussels, Belgium
  • 3Psychiatry Unit, Cliniques de l’Europe, Brussels, Belgium
JAMA Oncol. 2017;3(9):1174-1175. doi:10.1001/jamaoncol.2016.5490

As a dual board–certified hematologist and palliative care physician, I am convinced that numerous patients with advanced hematologic malignant neoplasms would benefit from early palliative care intervention, given that many of them will not be cured, and suffer from several distressing symptoms. However, for this patient population, early palliative care access is still uncommon, and far less common than for patients with solid tumors. Many patients with advanced hematologic malignant neoplasms receive aggressive treatments or chemotherapy while nearing the end of life and often die in the intensive care unit, even though it is not consistent with their expressed wishes.1

Add or change institution